Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects (NSERC partnered)

University of Toronto

$291,825.00

Advanced Bioreactors for Evaluation and Systematic Optimization of Decellularization and Recellularization of the Lung and Trachea

EF 2017-18

Résumé
Diseases affecting the airways are an important clinical problem and for the majority of patients with end-stage disease, transplantation of lung and/or trachea has become the only life-saving option. Ideally we need access to 'off-the-shelf' replacement grafts reducing the dependency on donor organs, wait-time and risk of death. In the lung, organ regeneration is achieved by using biohybrid devices with partially synthetic or natural scaffolds. The approach is to utilize advanced bioreactors operating under optimized physiological conditions to repopulate with new cells, scaffolds in which the resident cells have been removed, and use for functional replacement of damaged tissue. While transplantation of regenerated whole lungs is a far-off goal, we exploit the simpler system of the trachea with which we have extensive expertise while addressing key issues that will set the foundation for future clinical application of whole lung grafts. At the end of the funding period, we expect to begin clinical translation of a functional tracheal biograft used to address small airway and larger tracheal defects, respectively. The optimized tracheal bioreactors developed can result in commercial products via licensing to already existing lung biotech companies or through company creation ventures with focus on enhanced organ-specific bioreactors. In addition, the development of a computational model of fluid flow using a computerized geometrical models of vascular (and airway) networks will allow in silico experimental programs to explore strategies for targeted cell delivery. Models developed here have the potential for significant impact in lung tissue engineering, and can be applied to research groups focused on other organs. Completion of this work will set in motion a therapeutic strategy with the potential to save lives and vastly improve the quality of life of Canadians suffering from end-stage lung disease.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
376742
Name
Amon Cristina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Advanced Bioreactors for Evaluation and Systematic Optimization of Decellularization and Recellularization of the Lung and Trachea
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$291,825
Cihrequipment2
$52,100
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Airway Regeneration; Biological Scaffolds; Bioreactor; Decellularization; In Silico Modelling; Lung; Recellularization; Systematic Process Optimization; Tissue Engineering; Trachea
Abstract
Diseases affecting the airways are an important clinical problem and for the majority of patients with end-stage disease, transplantation of lung and/or trachea has become the only life-saving option. Ideally we need access to 'off-the-shelf' replacement grafts reducing the dependency on donor organs, wait-time and risk of death. In the lung, organ regeneration is achieved by using biohybrid devices with partially synthetic or natural scaffolds. The approach is to utilize advanced bioreactors operating under optimized physiological conditions to repopulate with new cells, scaffolds in which the resident cells have been removed, and use for functional replacement of damaged tissue. While transplantation of regenerated whole lungs is a far-off goal, we exploit the simpler system of the trachea with which we have extensive expertise while addressing key issues that will set the foundation for future clinical application of whole lung grafts. At the end of the funding period, we expect to begin clinical translation of a functional tracheal biograft used to address small airway and larger tracheal defects, respectively. The optimized tracheal bioreactors developed can result in commercial products via licensing to already existing lung biotech companies or through company creation ventures with focus on enhanced organ-specific bioreactors. In addition, the development of a computational model of fluid flow using a computerized geometrical models of vascular (and airway) networks will allow in silico experimental programs to explore strategies for targeted cell delivery. Models developed here have the potential for significant impact in lung tissue engineering, and can be applied to research groups focused on other organs. Completion of this work will set in motion a therapeutic strategy with the potential to save lives and vastly improve the quality of life of Canadians suffering from end-stage lung disease.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Amon, Cristina; Keating, Armand; Waddell, Thomas K
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $291,825~ $52,100~